Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/06—Tripeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/07—Tetrapeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/004—Aftersun preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to a composition having an effect of promoting production of type I collagen produced by human skin fibroblasts.
• Collagen occupies about 1Z3 of in vivo protein and is present in a large amount in blood vessels, skin, and bone, and plays an important role in the formation and construction of these tissues as a scaffold for cells.
• Collagen was considered to be a protein with low nutritional value because it is hardly degraded by digestive enzymes, but it promotes metabolism by ingesting collagen (Patent Document 1), hair growth promotion (Non-Patent Document 1), arthropathy Use as a therapeutic drug (Patent Document 2) has been reported, and its effectiveness has been reviewed. Furthermore, since collagen decreases with age, it is considered to contribute to the generation of wrinkles and sagging due to weakening of blood vessels, elasticity of skin, and a decrease in flexibility.
• Gelatin which is a heat-denatured product of collagen, is used as a food texture improver and cosmetics (Patent Document 3) using its high viscosity, coagulation, and water retention.
• untreated collagen and gelatin are highly viscous and easily coagulate, so those that have been partially hydrolyzed are often used.
• collagen since it is a protein, it has antigenicity, and there is a problem in the intake of allergy-integrated humans. Therefore, it has been reported that collagen is reduced in molecular weight by collagenase to be used as a protein source or an infusion preparation component for allergic patients who have lost antigenicity (Patent Document 4).
• Non-Patent Document 3 As for the physiological activity of collagen degradation products by collagenase, fibrin aggregation inhibitory activity (Patent Document 5) and anesthetic action (Non-Patent Document 2) are known. In addition, regarding collagen degradation products by collagenase derived from Clostridium histolyticum, it has been reported that 36% of the tripeptide produced is the most in Gly-Pro-Hyp (Non-patent Document 3).
• Patent Document 6 An attempt has been made to use a topical skin preparation containing a collagenase containing collagenase containing Gly-Pro-Hyp as an active ingredient for the purpose of anti-skin aging such as wrinkles.
• Patent Document 7 a collagen degradation product by collagenase containing Gly-Pro-Hyp and a collagen degradation product containing a molecular weight of 400 or less in particular has been developed (Patent Document 7). It is considered that it promotes collagen synthesis.
• Non-patent document 4 Lys-Thr-Thr-Lys-Ser
• pentapeptide derived from ⁇ 1 collagen degradation product and Gly, a tripeptide derived from a2 collagen degradation product.
• His— Lys Non-Patent Document 5
• Gly—G1u-Pro-Arg Non-Patent Document 6
• a pentapeptide derived from the degradation product of immunoglobulin G has been developed.
• Retinol a retinoic acid and its derivative
• Non-Patent Document 9 skin irritation and safety problems
• various components and compositions for increasing biological collagen have been developed, but they have not achieved a sufficiently effective action while having safety.
• the present invention has been completed by finding that when silybin and various peptides are used in combination, each of them has a synergistic action for promoting the production of type I collagen rather than the single use of each.
• Patent Document 1 JP-A-7-278012
• Patent Document 2 JP-A 63-39821
• Patent Document 3 JP-A 52-111600
• Patent Document 4 JP-A-7-82299
• Patent Document 5 JP-A-6-46875
• Patent Document 6 Patent No. 3504205
• Patent Document 7 JP 2001-1310844
• Patent Document 8 WO2004Z085429
• Patent Document 9 JP 2002-173424
• Patent Document 10 JP-A-5-286864
• Patent Document 11 Patent No. 2948818
• Patent Document 12 Japanese Unexamined Patent Publication No. 2000-169328
• Patent Document 13 Japanese Unexamined Patent Publication No. 2000-169332
• Patent Document 14 # 112002- 255448 ⁇ -Patent Document 15: Japanese Patent Publication No. 5-9406
• Patent Document 16 Japanese Patent Publication No. 63-41396
• Patent Document 17 Japanese Patent Laid-Open No. 2002-255847
• Non-patent literature 1 Nutrition Reports International, 13, 579, 1976
• Non-patent literature 2 Br. Pharmacol., 69, 551, 1980
• Non-Patent Document 3 Biochem., 50, 486, 1961
• Non-Patent Document 4 Biol. Chem., 268 (14), 9941-9944, 1993
• Non-Patent Document 5 Ann. NY Acad. Sci., 580, p573
• Non-patent document 6 Int J Pept Protein Res., 17 (4), p430-435., 1981
• Non-patent document 7 Invest. Dermatol., Vol.94, No.5, p717-723, 1990
• Non-patent document 8 Varani J., et al., J Invest. Dermatol., 116, 480—
• Non-Patent Document 9 Zouboulis, C.C., Retinoids: Is there a New Approach? , IFSCC Magazine, Vol.3, No.3, 2000
• Non-Patent Document 10 Wagner, H., etal., Arznein. Forsch, 24, 466, 1974.
• Non-Patent Document ll Tittel, G., etal., J. Chromatogr., 135, 499, 1977.
• Patent Document 12 Tittel, G., etal., J. Chromatogr., 153, 227, 1978.
• Non-Patent Document 13 Quercia, V., etal., Chromatography in Biochemistry, Medicine and Environmental Research, Frigerio A. (Ed)., Elsevier Scientific
• Non-Patent Document 14 Lowry, 0. et. Al., J. Biol. Chem., 193, 265, 1951
• Non-Patent Document 15 M. J. Barttek, etal., J. Invest. Dermatol., 58, 114, 1972 Disclosure of Invention
• An object of the present invention is to provide a composition that promotes the production of type I collagen in human dermal fibroblasts.
• the present inventor has studied to increase the production of type I collagen more effectively. As a result, the inventors have found that when a collagen-derived peptide that acts as a collagen raw material to promote collagen production and silybin are used in combination, the production of type I collagen is synergistically promoted, and the present invention has been completed.
• the present invention relates to a composition for promoting type I collagen production, comprising 1 silybin and a peptide that promotes collagen production, and 2 a peptide that promotes collagen production is Gly-Pro-Hyp
• composition according to any one of claims 1 to 4, which is for prevention and Z or improvement of wrinkles, sagging, dullness, blotches, 4 silybin and Gly—Pro—Hyp, Gly—His—Lys, Peptide power consisting of the amino acid sequence of Lys—Thr—Thr—Lys—Ser or Gly—Glu—Pro—Arg Cosmetics characterized by containing one or more selected, 5 Silybin and Gly—Pro — Hyp, Gly -His -Lys, Lys— Thr— Thr— Lys A peptide comprising the amino acid sequence of — Ser, or Gly— Glu— Pro— Arg, wherein the food is characterized by containing one or more selected, and is for 6 animals. Composition.
• composition of the present invention By using a combination of silybin and a peptide that promotes collagen production, a composition excellent in the effect of promoting the production of type I collagen in human dermal fibroblasts could be provided.
• the composition of the present invention By applying the composition of the present invention as a cosmetic or ingesting it as a food, it can be expected to improve skin elasticity and elasticity and prevent, prevent and improve wrinkles and sagging.
• composition of the present invention is highly safe for the skin.
• FIG. 1 A diagram showing the detection of type I collagen production by Western blotting in a three-dimensional skin model of silybin, silydinin, and silicristin.
• FIG. 2 A diagram showing the result of FIG. 1 numerically obtained by image analysis processing is shown.
• FIG. 3 Western blotting of type I collagen production in a three-dimensional skin model of a tripeptide with a Gly-Pro-Hyp (G-P-Hyp) sequence
• FIG. 4 A diagram showing the result of FIG. 2 numerically obtained by image analysis processing is shown. Gly—Pro—Hyp was described as G P—Hyp.
• FIG. 5 Western blotting shows the production of type I collagen in a three-dimensional skin model of tripeptides and silybins of the Gly-Pro-Hyp (referred to as G-P-Hyp) sequence.
• FIG. 6 A diagram showing the result of FIG. 3 numerically obtained by image analysis processing. Gly—Pro—Hyp was described as G P—Hyp.
• FIG. 3 is a diagram in which the production of type I collagen in a three-dimensional skin model of peptides and silybin (described as G—Q—P—R) was detected by West stamping.
• FIG. 8 A diagram showing the result of FIG. 7 numerically obtained by image analysis processing. Lys—Thr—Thr—Lys—Ser is described as KTTKS, Gly—His—Lys as G—H—K, and Gly—Glu—Pro—Arg as G—Q—P—R.
• FIG. 10 A diagram showing the result of FIG. 9 numerically obtained by image analysis processing. Lys-Thr-Thr-L ys— Ser with K— T— T— K— S, Gly— His— Lys with G— H— K, Gly— Glu— Pro Arg with G— Q— P— R Describe.
• Silymarin (CAS No. 65666—07—1) is extracted from the asteraceae Marian Thistle (scientific name: Shilibum marianum Gaertn, also known as Greater Thistle, Greater Thistle, Milk Thistle; CAS No. 84604-20-20) Is a generic name for flavonolidanane, which is expressed by the molecular formula CHO (Silvbin; CAS No. 22888—70—6),
• Non-Patent Document 10 Composition containing Silydianin (CAS No. 29782—68— 1), Silychristin (CAS No. 33889—69—9), Isosilybin (CAS No. 72581-71 —6), etc.
• the composition containing these flavonolidananes contained in the extract of thistle is referred to as silymarin as in the prior art.
• Silymarin is a mixture of flavonolidanane as described above, and the plant extract as silymarin and the content in the plant are determined by a method based on measurement with a spectrophotometer (Non-patent Document 11), a method by thin layer chromatography.
• Non-patent document 9 Non-patent document 9
• Non-patent documents 12 to 14 a method by high performance liquid chromatography
• 2,4-dinitrohydrazine analysis one of the methods based on spectrophotometer measurements, has been reported to the German Pharmacopoeia (monograph on fruits of Silybum marianum) and is widely used. It has been.
• Silymarin has long been used in Europe for the purpose of preventing and treating liver diseases. Moreover, it is widely known as an anti-oxidation agent.
• a useful composition for the skin a preparation for treating psoriasis and atopic dermatitis (Patent Document 10), containing a complex of flavonolidanane and phospholipid as an active ingredient, erythema, burns, dystrophic condition of skin or mucous membrane, Composition useful for treatment of dermatitis, prevention of skin aging and protection from external environment such as radiation, wind and sun (Patent Document 11), epidermal permeation barrier strengthening agent (Patent Document 12), sebum Secretion inhibitor (Patent Document 13), Composition for preventing skin aging to prevent, prevent and improve flattening of the epidermis (Patent Document 14), Cosmetics for preventing skin aging caused by antioxidant ability (Patent Document 15) ), A composition for promoting type I collagen production in human skin fibroblasts and a three-dimensional
• Silymarin is usually marketed as an extract raw material that is extracted from the seeds of maria thistle with ethanol, ethyl acetate, acetone, etc., and obtained as a dry powder by spray drying.
• Silybin used in the present invention is prepared in this way, and commercially available silymarin containing silybin can be used as it is. Further, an extract obtained by concentrating silybin from maria thistle and silybin can be isolated and purified and used as a compound.
• the plant body containing silybin in the present invention includes all parts such as leaves, stems, buds, flowers, woody parts, bark parts (crusts), ground parts such as roots and tubers, seeds, and rosin.
• the site can be used.
• the silybin and the plant body containing the same in the present invention can be used as a dried product obtained by drying itself and a dissolved product obtained by dissolving them using various solvents.
• it can be used as a dissolved solution using water or alcohols such as ethanol and methanol, polyhydric alcohols such as propylene glycol and 1,3-butylene glycol, and organic solvents such as ether, acetone and ethyl acetate.
• the plant body containing silybin in the present invention can be used as it is after natural drying, hot air drying, freeze drying, or fermentation. Further, when preparing a plant extract, it is possible to use a product obtained by performing extraction, concentration, powdered koji treatment, etc. according to a conventional method.
• the peptide for promoting collagen production of the present invention includes Gly—Pro—Hyp, Gly-His—Lys, Lys—Thr—Thr—Lys—Ser, or Gly—Glu—Pro—Arg amino acid sequence. Preferable peptide!
• Gly—Pro—Hyp is characterized by collagenase or gelatin component by collagenase. It is a peptide composition obtained by differential degradation and is known to be digested and absorbed more rapidly and efficiently than conventional collagen, gelatin or a hydrolyzate thereof (Patent Document 17). As described above, regarding collagen degradation products by collagenase derived from Clostridium histolyticum, it is reported that 36% of the produced tripeptides are the most in Gly—Pro—Hyp (Non-patent Document 3). In particular, it is an efficient production method for Gly—Pro—Hyp. Gly-Pro-Hyp used in the present invention may be chemically synthesized.
• Gly-His-Lys used in the present invention may be a product obtained by degrading oc2 procollagen with a collagen degrading enzyme such as coranase.
• a chemically synthesized product may be used.
• Lys-Thr-Thr-Lys-Ser used in the present invention may be a product obtained by decomposing oc 1 procollagen with a collagenolytic enzyme such as colanase.
• a chemically synthesized product may be used.
• Gly-Glu-Pro-Arg used in the present invention may be a product obtained by degrading immunoglobulin G with a degrading enzyme such as trypsin.
• a chemically synthesized product may be used.
• the composition for promoting the production of type I collagen of the present invention promotes the production of type I collagen, which is the main protein constituting the extracellular matrix of the dermis, and improves the skin's elasticity and elasticity. Prevents, prevents, and improves the formation of wrinkles and sagging caused by UV irradiation, etc., and keeps the skin youthful.
• composition for promoting the production of type I collagen of the present invention can be produced as an external preparation for skin such as a cosmetic or a food for oral use.
• silybin as a source of silybin, silymarin, either a plant containing silybin or a plant extract thereof, and Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys -A peptide selected from Ser, Gly—Glu—Pro—Arg can be used directly or added to wheat germ oil or olive oil as a cosmetic ingredient to produce a cosmetic.
• Examples of food include silybin and plant bodies containing silymarin and silybin as a source of silybin. Or one of its plant extracts and a peptide selected from Gly-Pro-Hyp, Gly—His— Lys, Lys—Thr-Thr-Lys-Ser, Gly—Glu—Pro—Arg directly or It can be used as a food with various nutritional ingredients added, or may be blended into a desired food.
• suitable auxiliaries such as starch, lactose, maltose, vegetable oil powder, cocoa butter powder, stearic acid, etc.
• edible forms such as granules, granules, tablets It can be formed into capsules, pastes, etc.
• processed meat products such as ham and sausage
• marine processed foods such as power boiled rice, chikuwa, bread, confectionery, butter, powdered milk, fermented milk products
• beverages such as milk and soft drinks.
• the combination ratio (molar ratio) between silybin and various peptides in the composition for promoting collagen production of type I of the present invention is appropriately selected and determined depending on the preparation method of each component, the form of the preparation, etc. Although not limited, it is preferable to combine 2 to 6 of various peptides with respect to 1 for silybin.
• the effective blending amount of the type I collagen production-promoting yarn and composition of the present invention, cosmetics, and the peptide that promotes the production of silybin and collagen depends on the preparation method of each component, the form of the formulation, etc. However, when used as an external preparation for skin, it is preferable to contain 0.01 to 2% by weight of a peptide that promotes production of silybin and collagen, respectively. On the other hand, when it is used as a food as a tablet or drink, it is preferable to contain 0.1 to 10% by weight.
• Effective application amounts of the composition for promoting production of type I collagen, cosmetics, and food of the present invention can be appropriately determined according to the application route, application schedule, formulation form, and the like. For example, it can be appropriately adjusted in the range of 0.01 to 10 g per day, and can be applied once or several times.
• the food can be used directly or with various nutritional components added.
• suitable auxiliaries such as starch, lactose, maltose, vegetable oil powder, cacao butter powder, stearic acid, etc.
• it can be used in edible forms such as granules, granules, It may be molded into tablets, capsules, pastes, etc., and used as food supplements, health functional foods, etc., and edible.
• Various foods for example, processed meat products such as ham and sausage, fishery products such as kamaboko and chikuwa Used by adding to processed food, bread, confectionery, butter, milk powder, fermented dairy products It may be used by adding to beverages such as water, fruit juice, milk, and soft drinks.
• Such agents and foods can be produced by a formulation technique that is usually employed.
• the cosmetic can be directly or added to wheat germ oil or olive oil and used as a cosmetic ingredient, and the cosmetic can be produced using these.
• composition for parenteral application is in the form of, for example, a solution such as an aqueous solution, oil, emulsion, suspension or the like, a semi-solid agent such as a gel or a talium, a solid agent such as a powder, a granule, a capsule, a microcapsule or a solid.
• a solution such as an aqueous solution, oil, emulsion, suspension or the like
• a semi-solid agent such as a gel or a talium
• a solid agent such as a powder, a granule, a capsule, a microcapsule or a solid.
• Conventional power Prepared in these forms by known methods, and used in various dosage forms such as lotions, emulsions, gels, creams, ointments, plasters, haps, aerosols, suppositories, injections, powders, etc. can do. These can be applied to the body by applying, sticking or spraying.
• lotions, emulsions, creams, ointments, plasters, haptics, aerosols and the like are particularly suitable for external skin preparations.
• Cosmetics include skin lotions such as lotions, emulsions, creams, knocks, makeup base lotions, makeup creams, emulsions, creams or ointment foundations, lipsticks, eye colors, cheek colors.
• Makeup cosmetics such as hand creams, red creams, body cosmetics such as body lotions.
• bulking agents include sugars such as glucose, ratatoose, maltose and sucrose, sugar alcohols such as sorbitol, processed starches such as dextrin and cyclodextrin, starches such as wheat starch and corn starch, proteins such as casein and soy protein, Gum arabic, sodium alginate, sodium caseinate, gelatin, pectin, powdered cellulose, carboxymethyl cellulose and other polymer stabilizers, lecithin, sucrose fatty acid ester, propylene glycol fatty acid ester, glycerin fatty acid ester and other emulsifiers, calcium powder Etc. can be used
• the composition for promoting production of type I collagen, cosmetics, and food of the present invention may contain a compound having an antioxidant action.
• the compound exhibiting an antioxidant action is not particularly limited, and examples thereof include various vitamins, various polyphenols such as rutin, tocotrienol, coenzyme Q10, and natural components containing them.
• the composition for promoting production of type I collagen, cosmetics, and food of the present invention include abnormal tans in vivo.
• a component that promotes accumulation and removal of the protein can be included.
• the component that promotes the accumulation and removal of abnormal proteins in the living body is not particularly limited, and examples thereof include soybean saponin, kale extract, silane extract, and iris extract.
• oils and fats examples include liquid oils such as camellia oil, evening primrose oil, macadamia nut oil, olive oil, rapeseed oil, corn oil, sesame oil, jojoba oil, germ oil, wheat germ oil, darice trioctanoate, and cacao oil ,
• coconut oil hydrogenated coconut oil, palm oil, palm kernel oil, molasses, owl kernel oil, hydrogenated oil, hardened castor oil and other solid oils, beeswax, candelilla wax, cotton wax, nukarou, lanolin, lanolin acetate
• liquid oils include waxes such as lanolin and sugarcane wax.
• hydrocarbons examples include liquid paraffin, squalene, squalene, and microcrystalline wax.
• higher fatty acids examples include lauric acid, myristic acid, normitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA).
• higher alcohols include linear alcohols such as lauryl alcohol, stearyl alcohol, cetyl alcohol, and cetostearyl alcohol, branched alcohols such as monostearyl glycerin ether, lanolin alcohol, cholesterol, phytosterol, and otatilde decanol. It is done.
• silicones examples include linear polysiloxanes such as dimethylpolysiloxane and methylphenol polysiloxane, and cyclic polysiloxanes such as decamethylcyclopentasiloxane.
• fatty acid salt such as sodium laurate
• higher alkyl sulfate ester salt such as sodium lauryl sulfate
• alkyl ether sulfate ester salt such as POE lauryl sulfate triethanolamine
• acyl sarcosine acid such as sodium laurate
• sulfosuccinic acid salt such as N-acyl amino acid salt and the like.
• cationic surfactants include alkyltrimethylammonium salts such as stearyltrimethylammonium chloride, benzalkonium chloride, and benzethonium chloride. I can get lost.
• amphoteric surfactants examples include betaine surfactants such as anolenoquinobetaine and amide betaine.
• nonionic surfactants include sorbitan fatty acid esters such as sorbitan monooleate and hardened castor oil derivatives.
• antiseptics examples include methyl paraben and ethyl paraben.
• sequestering agent examples include edetic acid salts such as disodium ethylenediamine tetraacetate, edetic acid, and sodium edetate.
• polymer examples include gum arabic, tragacanth gum, galactan, guar gum, carrageenan, pectin, agar, quince seed, dextran, pullulan, carboxymethyl starch, collagen, casein, gelatin, methylcellulose, methylhydroxypropenoresorellose, hydroxy
• examples thereof include beryl polymers, bolenomethylenorescenellose sodium (CMC), sodium alginate, beryl polymers such as carboxybule polymers (CARBOPOL, etc.), and the like.
• Examples of the thickener include carrageenan, gum tragacanth, quince seed, casein, dextrin, gelatin, CMC, hydroxyethyl cellulose, hydroxypropyl cellulose, canoleboxybi-nole polymer, guar gum, xanthan gum, bentonite and the like. it can.
• Examples of the powder component include talc, kaolin, mica, silica, zeolite, polyethylene powder, polystyrene powder, cellulose powder, inorganic white pigment, inorganic red pigment, titanium oxide coated My power, titanium oxide coated talc, Examples thereof include pearl pigments such as colored titanium oxide coated my power, and organic pigments such as red 201 and red 202.
• Examples of the ultraviolet absorber include noraminobenzoic acid, phenyl salicylate, isopropyl methoxy cinnamate, octyl paramethoxy cinnamate, 2,4-dihydroxybenzophenone, and the like.
• ultraviolet blocking agent examples include titanium oxide, tanorek, power noremin, bentonite, kaolin, and zinc oxide.
• humectant for example, polyethylene glycol, propylene glycol, dipropylene Glycol, 1,3 butylene glycol, 1,2 pentanediol, glycerin, diglycerin, polyglycerin, xylitol, maltitol, maltose, sorbitol, glucose, fructose, sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, pyrolidone carboxylic
• acids and cyclodextrins include acids and cyclodextrins.
• Examples of medicinal ingredients include vitamin A oil, vitamin A such as retinol, vitamin B such as riboflavin, B such as pyridoxine hydrochloride, L-corsic acid, L-ascorbi
• Phosphoric acid ester L-ascorbic acid monopalmitic acid ester, L-ascorbic acid dipalmitic acid ester, L-ascorbic acid 2-Dalcoside and other vitamins C, pantothenic acids such as calcium panthenate, vitamin D, cholecalciferol Etc. Vita
• Min D vitamins such as vitamin E such as a-tocopherol, tocopherol acetate, and nicotinic acid DL-a-tocopherol.
• Whitening agents such as placenta extract, dartathione, yukinoshita extract, skin activators such as royal jelly, linden extract, kabusaicin, gingeron, cantalis tincture, ictamol, caffeine, tannic acid, gamma oryzanol and other blood circulation promoters, glycyrrhizin Examples include acid derivatives, glycyrrhetinic acid derivatives, anti-inflammatory agents such as azulene, amino acids such as arginine, serine, oral isine and tributophan, maltose sucrose condensates of resident bacteria control agents, and lysozyme chloride.
• force honey extract parsley extract, beech extract, wine yeast extract, grape funoles extract, squirrel extract, rice extract, budu extract, hop extract, rice bran kiss, bean extract, lobata extract, succulent extract, assembly extract, melilot extract, perch extract, Licorice extract, peonies extract, svono extract, loach extract, capsicum extract, lemon extract, gentian extract, perilla extract, aloe extract, rosemary extract, sage extract, thyme extract, tea extract, seaweed extract, cucumber kiss, chioji extract, carrot extract,
• Examples include various extracts such as horse chestnut extract, wild bean extract, cucumber extract and the like.
• a three-dimensional skin model was prepared by adding an appropriate amount of a solution obtained by dissolving Silibin (Sigma Aldrich) with biochemical reagent grade dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries, Ltd.) to the culture solution.
• Silibin Sigma Aldrich
• DMSO biochemical reagent grade dimethyl sulfoxide
• Silazinin and silicristine were fractionated by the following method. Dissolve 2 g of silymarin (Sigma Aldrich) in 10 ml of ethanol, fractionate it into 200 ml of ODS column (FUJISILYSIA CHEMICAL DM1020T) using a solvent condition with a water to methanol ratio of 1: 1, A slyristine sparse fraction was obtained.
• Silicanin sparse fraction and silycristin sparse fraction were each fractionated on silica gel chromatography 200ml under a solvent condition of 95: 5 ratio of black mouth form to methanol, 17mg of purified silychristin and 34mg of purified silydinine Obtained.
• An appropriate amount of a solution obtained by dissolving a purified product of silycristin and a purified product of silidianin with biochemical reagent grade dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries, Ltd.) was added to the culture solution and processed into a three-dimensional skin model.
• Lys-Thr-Thr-Lys-Ser, Gly-His-Lys, and Gly-Glu-Pro-Arg were commissioned by Nikka Techno Service Co., Ltd. and synthesized according to conventional methods. After synthesis, it was purified by reverse phase HPLC. It was confirmed by amino acid analysis and purity analysis by reverse phase HPLC that the target peptide was synthesized with a purity of 90% or more. A solution in which these peptides were dissolved in dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries, Ltd.), a biochemical reagent, was added to the culture solution in an equivalent amount and processed into a 3D skin model.
• DMSO dimethyl sulfoxide
• the three-dimensional human skin model is widely used for safety evaluation and efficacy evaluation as a pseudo model of human skin.
• TESTSKIN LSE-high (Toyobo Co., Ltd.) was used as the three-dimensional human skin model.
• the cells were immersed in a secondary antibody (horseradish peroxidase-labeled anti-usagiimmunoglobulin G prepared to 250 ng Zml with a washing solution) and allowed to react at room temperature for 1 hour. After washing, detection was performed using an ECL plus western plotting detection reagent (Amersham Biosciences). Further, the detected bands were captured using an image scanner (Amersham Science) and then analyzed and digitized using Image Master Software (Amersham Bioscience).
• a three-dimensional model of human skin was treated with 10 / zg / ml silybin, silyristine, and silydinin at a concentration of 10 ⁇ each, and the amount of type I collagen was measured by Western blotting.
• Figure 1 shows the detected bands
• Figure 2 shows a graph of the detected bands.
• silybin a component of silymarin, contained in 10 ⁇ g / mU silymarin, was treated with 10 ⁇ ⁇ , type I collagen production was 2.3 and 3.2 times, respectively, compared to the untreated control. (Fig. 1 and Fig. 2).
• silystin and silydinin which are components contained in silymarin
• type I collagen production was 0.95 and 0.9 times that of the untreated control, respectively (Fig. 1 and Figure 2). Therefore, it became clear that the active ingredient involved in the promotion of type I collagen production contained in silymarin is silybin.
• FIG. 5 shows a graph showing the obtained band.
• Figure 7 shows the detected bands
• Figure 8 shows a graph of the detected bands.
• Lys-Thr-Thr-Lys-Ser, Gly -His -Lys, Gly—Glu—Pro—Arg 10 ⁇ M each, silybin 5 ⁇ alone, Lys—Thr—Thr— Lys— Ser, Gly — His— Lys, Gly— Glu— Pro— Arg 10 ⁇ M and silybin 5 ⁇ each were processed into a three-dimensional human skin model, and type I collagen production was measured.
• the obtained band is shown in FIG. 9, and a graph showing the obtained band is shown in FIG.
• composition (Mixed amount; mg) Maria thistle extract (containing 35% Libin) 25 Soy extract (containing 80% soybean saponin) 25
• composition (Amount to be blended; mg) Maria thistle extract (containing 35% silybin) 25 Soy extract (containing 80% soy saponin) 25
• composition (Amount to be blended; mg) Maria thistle extract (containing 35% silybin) 25 Soy extract (containing 80% soy saponin) 25 Lys—Th “—T h” —Lys— Se ”(peptide) 25 Cellulose 40 Starch 20 Sucrose fatty ester 2
• composition (Blending amount; mg)
• Soy extract (containing 80% soy saponin) 25
• composition (Nishimiai: ⁇ ; mg)
• Soy extract (containing 80 3 ⁇ 4 soy saponin) 25
• Soy extract (containing 85% soy saponin) 1. 00
• composition [Composition: Mass 1 ⁇ 2)
• the following components (1) to (12) are heated and dissolved at 80 ° C to form an oil phase.
• Ingredients (13) to (15) are heated and dissolved at 70 ° C to form an aqueous phase.
• the aqueous phase was gradually added to the oil phase to emulsify, cooled to 40 ° C with stirring, and further cooled to 30 ° C with stirring to obtain a cream.
• the following components (1) to (12) are heated and dissolved at 80 ° C to form an oil phase.
• Ingredients (13) to (15) are heated and dissolved at 70 ° C to form an aqueous phase.
• the aqueous phase was gradually added to the oil phase to emulsify, cooled to 40 ° C with stirring, and further cooled to 30 ° C with stirring to obtain a cream.
• the following components (1) to (12) are heated and dissolved at 80 ° C to form an oil phase.
• Ingredients (13) to (15) are heated and dissolved at 70 ° C to form an aqueous phase.
• the aqueous phase was gradually added to the oil phase to emulsify, cooled to 40 ° C with stirring, and further cooled to 30 ° C with stirring to obtain a cream.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Birds (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Alternative & Traditional Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37899496

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (35)

Citations (7)

Family Cites Families (20)

• 2005
  • 2005-09-29 JP JP2005283271A patent/JP4033877B2/ja not_active Expired - Lifetime
• 2006
  • 2006-07-20 CN CN2006800361751A patent/CN101277713B/zh active Active
  • 2006-07-20 WO PCT/JP2006/314393 patent/WO2007037060A1/ja not_active Ceased
  • 2006-07-20 US US12/088,655 patent/US8022038B2/en not_active Expired - Fee Related
  • 2006-07-28 TW TW101113938A patent/TWI438002B/zh active
  • 2006-07-28 TW TW095127790A patent/TW200740453A/zh unknown

Patent Citations (7)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events